Abgent is a biological reagents and custom services company located in Oxfordshire and headquartered in San Diego, CA. Our goal is to provide high quality, low cost products and services to support groundbreaking scientific research across the globe.
Abgent pride our customer services by consulting with you at critical project junctures and offer free lifetime technical support. We also offer a no-product/no-fee service so if we take your project on but don't complete it there will be no cost to you. We manufacture our products to GLP / GMP standard and provide customisation to meet every need. We guarantee confidentially at all times and are ISO9001 Certified.

Absynth Biologics is exploiting novel antigens to develop vaccines and therapeutic antibodies for the prevention and treatment of infections. The lead programme targets Staphylococcus aureus (S. aureus) a pathogen that causes life-threatening infections, made more important by the alarming spread of antibiotic resistant strains in hospitals and the community. To date S. aureus vaccines have filed to show efficacy in the clinic and choosing the appropriate antigens to include in such vaccines has proved to be a major challenge. The key criteria proposed for successful vaccine development are that antigens should be essential for survival and/or virulence, antibody accessible and expressed by all S. aureus isolates. Absynth has identified novel and proprietary S. aureus antigens that meet these key criteria. Supporting data in vitro has shown that these antigens have the potential to harness the human immune system and antibodies to the antigens inhibit S. aureus growth. In a gold-standard in vivo model of infection, the antigens reproducibly protect against infection and studies leading to candidate selection and clinical studies are in progress. Absynth's distinctive approach has identified protein antigens in a broad range of Gram positive and Gram negative bacteria. The S. aureus antibody programme is partnered with MorphoSys AG and Absynth is seeking investment for its next growth stage to advance the S. aureus vaccine programme to clinical trials and develop other vaccine programmes in its pipeline.

Alcyomics was founded in 2008 as a spin-out company from Newcastle University (UK). Alcyomics is the UK biologics and cellular therapeutics service company, offering the unique, non-artificial, Skimune™, Skin Explant Assay, for immunogenicity testing.

Currently available skin models are not exact copies of human skin in vivo and human-specific tissue is a must. It is well recognised that the tissue response from human skin is more predictive and acceptable than using animal skin testing.

Alcyomics bridge the gap between animal pre-clinical testing and first safety studies in man. By utilising a human tissue testing stage risks in drug development can be minimised, drug development times shortened and development costs reduced, using criteria similar to those used and observed in the clinical setting.

Almac is a financially stable, privately owned organisation with over 30 years experience. The Group provides integrated development solutions to over 600 customers worldwide including all the world leaders in the pharmaceutical and biotechnology sectors.
The company has over 3,300 employees and is headquartered in Craigavon, Northern Ireland; US operations are based in its new $120 million North American Headquarters located in Souderton PA. inaddition to North Carolina and California. Each customer is guaranteed a dedicated hands-on project management service to meet individual needs ensuring clients will experience continued success in all their ventures.
Almac provides a seamless, fast and efficient route from drug discovery through to market. Our range of services includes:

Research: Almac is focused on the delivery of biomarker solutions and supporting biomarker strategy for drug development, which underpins the delivery of personalised medicine.
Chemical & Pharmaceutical Development: Almac accelerates the development of customers' drug candidates through the effective integration of science and manufacturing to provide drug substance & product.
Clinical Development: Almac is unique in the industry, offering fully integrated world class clinical trial supplies & IVR/IWR technology.
Commercial: Almac provides solid dosage form commercial manufacture and packaging for EU & US markets. Commercial support services facilitate EU market access for non-EU product.

AvantiCell Science Ltd is a UK-based company that combines world-class scientific expertise with proprietary technologies to deliver a range of customised services and products to the drug discovery and development industry globally. Launched in 2006, AvantiCell has established a reputation for delivering assay results that are truly predictive of the efficacy and safety of the test materials when they enter the later stages of the drug development process.

AvantiCell provides advanced cell culture technology based on diseased and/or healthy primary cells to provide clients with physiologically-relevant human and animal cells that can be utilised for the evaluation of a wide range of test materials, including pharmaceuticals, traditional medicines, natural products, biomaterials, veterinary drugs, and agri-bio products. The quality and nature of the cells can save clients significant time and money in subsequent animal testing and clinical trials since they are a better representation of animal models than established cell lines. In addition to primary cells, AvantiCell can also offer stem cells.

AvantiCell delivers its technology as a mix of services and products customized for the convenience of its clients. Culture systems can be developed for screening programmes aimed at the evaluation of bioactivity and mode of action in test materials ranging from botanical extracts to single chemical entities. Alternatively, primary cell cultures can be provided in a form convenient to the client, including being pre-dispensed into 96-well plates. This unique service allows clients the certainty of cell supply without establishing in-house cell culture expertise and can be extended to complete assay kits.

BioPark, the ´Outer London´ science park offers life science businesses high quality start-up and grow-on space combined with comprehensive business support. A ´Virtual Office´ service is also available with mailbox and post forwarding, telephone answering, etc.
The chemistry and biology laboratories are well equipped with fume hoods and microbiological safety cabinets. Additionally dark rooms, autoclaves and freezer rooms are provided on site. There is also an open access biomarker lab for use by researchers.
BioPark covers around 9,000 square meters and offers a range of laboratory configurations in floor areas from 30 to 180 square metres - ideal for biotechnology, diagnostics and medtech research and development. Most laboratories have write-up areas and associated offices. Together with 24/7 security, BioPark also provides meeting conference and event facilities, including a 66-seat lecture theatre, for use by tenants and others.
Owned by and close to the University of Hertfordshire, the science park is ideally situated for national and international travel, being just 40 minutes from central London by train and having good road access to three London airports.
BioPark provides exceptional networking and collaboration opportunities as it sits at the centre of the Cambridge-Oxford-London research cluster, within which are located key clinical research centres, Universities, pharmaceutical multinationals and over 400 biotechnology companies.

BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.

Cambridge BioScience is a leading European distributor of cutting edge life science research products. For our Customers, we seek out the most exciting new technologies that will advance their research and help them to make breakthrough discoveries. For our Supply Partners we aim to bring their products to market as quickly and effectively as possible.

Technology:
- Ion Channel cell lines and predictive cardiac safety screening services
- GPCR cell lines and screening assays
- Human tissue and primary cells. Sourcing of high quality tissues, cells and biofluids
- Scalable pluripotent stem cell culture system
- High potency growth factor technology

cddi is an international biotechnology and pharmaceutical consulting company, led by a full time core management team of senior people who have developed more than 30 products globally from discovery to market. Our Managing Partners personally direct a global network of people that cover a wide range of drug development expertise with skills to operate in all project areas. Since formation, we have worked with both large pharma and small biotechs, as well as with investment companies.

cddi's Managing Partners and our people focus on operational management as well as strategic direction. Unlike a traditional consultancy who talk and advise, our mode of working is hands-on and delivery focused. With our extensive industry experience and the expertise of our people, we will achieve your specific objectives faster and more cost-effectively.

The focus of our company is the neurodegenerative condition of dementia, and in particular Alzheimer�s disease, the most common cause of dementia. Our mission is to find and develop novel treatments for Alzheimer�s disease that offer meaningful and lasting benefits to those afflicted with this condition. We aim to achieve our objective using a diversified business model, offering both entrepreneurial and consulting services. We seek to partner on opportunities where we can leverage our experience and contact network to expedite bringing new therapies to market in a cost effective manner. We are actively pursuing new methods of innovation and drug development, including open source development. The World Health Organisation estimates that there are currently about 18 million people worldwide with Alzheimer�s disease. This figure is projected to nearly double by 2025 to 34 million. Alzheimer�s disease has a cascade effect in society, affecting not only the sufferer but also their partners, family, friends and carers. The economic cost of the condition represents both a major fiscal and social cost to society as a whole. We invite you to contact us so that we can work together towards solutions for Alzheimer�s disease.

CrystecPharma applies the latest supercritical fluid technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec supercritical fluid technologies can be applied to both small drug molecules and biotechnologically sourced drugs.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.
The CrystecPharma team consists of the some of the world's leading scientists in the field of supercritical fluid technology-based pharmaceutics, including Professor Peter York. The first product manufactured using this technology is planned to launch next year.
Our technology and extensive knowhow enable us to provide the following product solutions:
- Crystal and particle engineering for targeted delivery and enhanced product performance
- Stabilisation and rapid reconstitution of molecules derived from biotechnology
- Formation of pure metastable forms that have enhanced solubility and which demonstrate enhanced physical and chemical stability
- Improved inhaled and nasal delivery through optimised particle design
Crystec is a Medilink member.

Diamond Pharma Services is a leading technical and scientific consulting group serving the biotechnology and pharmaceutical industry. Our emphasis is on the following areas:

• Regulatory Affairs: From Product Concept to Registration and Beyond
• Product Development: Nonclinical, CMC and Clinical Aspects
• Pharmacovigilance: Clinical trial (Phase I-IV), Post-Marketing and QPPV Services
• Compliance: GLP, GMP, GCP and QP Services
• Patient Information Leaflet Testing: Over 120 Tested with 100% Positive Agency Feedback

Our clients range from virtual start-up companies to the largest multi-national corporations. Our expertise includes products of recombinant DNA and hybridoma technology, nucleotide based products (RNA and DNA), synthetic peptides, chemical entities (innovative and generic), vaccines (therapeutic and prophylactic), blood products and advanced therapy medicinal products (gene therapy products).

We have sophisticated and well-equipped office facilities and a state-of-the-art IT system. Our IT system includes a fully validated in-house eCTD system (Extedo) and safety database (ARISg). The company was founded in 2005 by Dr. Maureen Graham, formerly Director of Regulatory Affairs at Amgen. Our specialised team of more than 24 professionals includes those with a broad and varied industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.

Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.
-LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.

The identified protein domains are then used to quickly develop binding/activity assays for use in small molecule hit screening. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging discovery programs. The Domainex services enhance drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.

ECCRO is a specialist provider of Phase II-IV clinical trial services in India. Having customised industry best practices for India, we deliver the region´s clinical trial potential in terms of cost and time savings at international standards of ethical integrity and data quality. We do this by partnering with clinical trial sites such that they are staffed with a trained ECCRO site manager whose role is to support ECCRO trials at the site. ECCRO´s operational office is in Mumbai, India however its international base is in London, UK to facilitate sponsor interaction and liaison with partner CROs.

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatology. Epistem's Contract Research Division has a track record of providing bespoke preclinical efficacy testing services to over 130 international clients in biotechnology, pharmaceutical and personal care sectors.

Through specialist knowledge of epithelial diseases, the scientists at Epistem have developed a range of unique in vitro and in vivo assay methodologies which can be used to assess the mode of action and efficacy of new drug candidates. With expertise in disorders of intestinal, breast, skin and oral epithelia, Epistem screens new compounds to assess their potential as anti-cancer agents, IBD agents, mucositis modulatory agents, cell cycle stimulators or inhibitors and wound healing regulators. Novel services that Epistem has recently introduced into its research service portfolio include an adoptive T-cell transfer IBD model, in vitro and in vivo cancer stem cell and angiogenesis assays and a unique plucked hair follicle cancer biomarker platform.

Food & Drug Analytical Services (FDAS) is a successful, independent, QC Laboratory, based in BioCity, Nottingham (UK). In October 2009 both the chemistry and microbiology cGMP facilities were reviewed and a successful audit was passed with another approval from the MHRA inspectors.

FDAS offers fast, customer driven QC analytical testing services to the pharmaceutical and heathcare industries, to a Global Market. FDAS performs a wide array of services including raw material and excipient testing, finished product analysis, product release, sterility, LAL, general microbiology and storage stability studies to pharmaceutical Manufacturing companies, and R&D facilities requiring cGMP.

FDAS is also particularly skilled in method development, validation and protocol design, and formulation.
Our experienced analytical team within our state of the art, GMP facility provide all the technical expertise needed to guarantee accurate, timely results that meet the requirements and rigours of any regulatory body (FDA/MHRA)

Fusion Antibodies is a world leader CMO in Antibody Sequencing; Antibody Engineering & Humanization and Expression and Purification of Pre-Clinical Grade Therapeutic & Diagnostic grade Proteins and cGMP scale up.

Antibody Cell line Sequencing
We can sequence from any antibody producing cell line. We have sequenced >500 antibodies from a variety of species with antibody variable domains sequenced from mouse, rat, bovine, human guinea pig, hamster, rabbits and human antibody secreting EBV cell lines.
Antibody Humanization
Fusion Antibodies have developed a technology for the rapid production of cell lines expressing fully humanized antibodies.
Antibody Engineering Services
ScFv / Fab Production: Fusion Antibodies have developed a technology to convert full monoclonal antibodies from a hybridoma cell line into single chain antibody fragments. These can be expressed in E. coli or CHO cells.
Antibody Chimerization: Fusion Antibodies have developed a technology for the rapid production of cell lines expressing full length recombinant antibodies.
Antibody Class Switching: Fusion Antibodies offers a service to switch IgM antibodies to IgG isotypes.
Expression and Purification of Pre-Clinical Grade Therapeutic & Diagnostic grade Proteins
We combine our bio-informatic and proteomic expertise to produce high quality recombinant protein to meet your requirements. Using FET Fusion can deliver your most challenging proteins. (FET is a multi parallel screening approach using a number of proprietary vector systems to speed up the production of your recombinant protein).

cGMP scale up
Fusion Antibodies can now deliver a full development package

HighQ delivers cloud-based solutions for secure document exchange and enterprise collaboration in the life science industry, working closely with CROs, Sponsors and health care providers. HighQ is used for specifically identified collaborative business processes within life science industry, some of which includes Mergers & Acquisitions, Partnering & Business Development, Licensing, Board Reporting, Legal Management, R&D Submissions, Q&A etc.

Service Offerings Overview

We offer contract services in formulation design and development from drug discovery support through to prototype clinical and commercial formulation for both small molecule and biopharmaceutical therapeutics; including access to a range of standard and proprietary technologies and expertise including particle size reduction, amorphisation, co-crystallisation and super critical fluid crystallisation. We have expertise over a range of dosage forms and our services are supported by a team of formulation and analytical scientists and a wide range of sophisticated analytical equipment.

Our services include:

• Providing a range of technologies and expertise focused on enhancing dissolution of poorly soluble APIs
  
• Designing and developing new formulations across a range of dosage forms
  
• Preformulation package including salt and polymorph screening
  
• Developing analytical methods for measuring the physical characteristics and purity of raw materials and pharmaceutical products
  
• Commercial formulation problem solving involving a range of analytical techniques
  
• Feasibility studies and design of inhaled therapeutic formulations

Technologies

• Particle size reduction - Nano-particle processing technologies
  
• Crystal engineering - Super Critical Fluid technologies
  
• Amorphisation - Melt extrusion technologies
  
• Co-crystallisation - Conventional and Melt extrusion technologies
  

Analytical Services

• Solid state analysis and optimisation including polymorph and salt screening
  
• Chemical analysis, method development and validation and stability studies
  
• Raman Mapping
  
• Microscopy and particle size analysis
  
• Full range of thermal analytical technique

Isogenica specialises in providing protein engineering services to pharmaceutical and biotechnology companies. Isogenica's core drug discovery platform, "CIS display", offers rapid discovery, identification and design of new peptide, polypeptide and antibody lead compounds. CIS display can quickly construct polypeptide libraries of unprecedented size and complexity in vitro, without the need for cloning. A library of up to a hundred trillion different clones can be easily generated in a few hours and quickly searched so that better products and motifs can be selected in just a few days. CIS display technology has provided hits and information against a wide range of targets and has advantages over alternative technologies. The technology is adaptable for the display of different proteins and licences are available for scFv and other polypeptide scaffolds. Isogenica is currently upgrading the platform by integrating high throughput screening and by automating the process. CIS display technology is available for non-exclusive licensing in defined fields of research, or available under fee-for-service use. More than a dozen partnering and licensing deals have been secured to date.

Systems for Cell Culture

Kirkstall has developed an advanced cell culture system to provide in vivo like conditions for cell growth.

By introducing flow of media and a variety of scaffold types into cell culture chambers, Kirkstall´s Quasi-Vivo® system provides a more physiologically representative conditions for cell growth than cultures grown in static wellplates.

The Quasi-Vivo® system has many applications in biotechnology:

• ADME & PKPD studies
• Disease modeling
• Safety & Toxicity screening

and looks particularly useful for regenerative medicine and stem cell research. It promises a way to control cell differentiation and phenotype without using a complex and expensive cocktail of growth factor chemicals in the media.

The system is already being used at leading universities across Europe.

Key Benefits of Quasi-Vivo® System

• Keeps precious and costly cells alive longer > 28 days for human hepatocytes
• Provides a ´Plug and play´ way to run biology experiments with easy to connect individual cell culture chambers that can house many kinds of scaffolds or cells, and may be the best way to control stem cell differentiation
• Scale is ideal for metabolism studies, with enough cells per chamber to produce detectable output by sampling conditioned media or cell culture, but small enough that many experiments can be run in parallel

Medilink (Yorkshire & Humber) Ltd is a private company which represents Life Science businesses in the UK region of Yorkshire & Humber, and through the Medilink UK network, life science businesses across the UK.

Medilink offer specialist consultancy services, including international partnering (technology exchange, joint intellectual property & technology licensing), joint venturing, international product placement, PR and marketing, and UK market access (including clinical trials & clinical engagement).

We are keen to meet with similar representative organisations that would be interested in developing partnerships in the UK. We would also like to hear from life science companies that may benefit from our services, particularly companies which may have a single technology and would gain value from partnering with UK companies with complementary technologies, or which would be interested in collaborating in product development.

Founded in 1999, Nexus Oncology has an excellent reputation for client service and has grown through recommendations from existing sponsors and study sites, as well as repeat business from satisfied clients. Nexus Oncology is a niche CRO with a reputation for excellence.

Our dedication to oncology and our in-depth understanding of this field has enabled us to attract and retain high calibre staff with extensive oncology experience. The therapeutic area specialisation means that our operation is optimised to work efficiently in this challenging area. Nexus Oncology staff are well respected by investigators, site staff and sponsors alike.

We offer a full range of drug development services.

Our project experience covers a wide range of solid and haematological tumour indications and therapeutic approaches.

O2h is the discovery services arm of Piramal Pharma Solutions Ltd, a global top 5 CMO, offering a unique full-service partnership at every stage of the pharma life-cycle. Piramal Pharma Solutions employs 2,500 people across 9 specialist sites in North America, UK and India. The Piramal group has a 140 year history and is publicly listed company (BSE: PIRAMALHE).

O2h's 200 employees work within its project management office in Cambridge, UK and its operations in Ahmedabad India. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based medicinal, synthetic chemistry, and process chemistry as well as in vitro biology services.

OET Ltd is a biotechnology company and centre of excellence for baculovirus based recombinant protein expression. OET provides protein expression products, services, consultancy and training to pharmaceutical and biotech companies and academic institutions. OET is also carrying out an extensive R & D programme.

OGT works with pharmaceutical clients for biomarker discovery and validation in the areas of target identification and companion diagnostics. Our capability set includes extensive experience in molecular diagnostics (NGS, aCGH, methylation, miRNA, cytogenetics, immune response profiling and single cell analysis). We are able to rapidly customise arrays and studies to client specifications. OGT integrates DNA, RNA and protein methodologies to deliver rapid, cost-effective biomarkers for dose response, toxicity, immune response and therapeutic dose monitoring.

Penn services include:
CMC Consultancy, Formulation Development, Analytical Development, Clinical Trial Supply, Contract Manufacturing, Qualified Persons Release Services, Paediatrics Formulation and Manufacturing, Hi-Potency capabilities, Orphan drug expertise, More than 30 Years of specials, manufacturing expertise, Comparator Sourcing.
The above offerings are all under one roof providing a strong and easy communication channel between departments making developments, manufacturing and analytical processes.

During ten years of development in Oxford, our computational modelling approach has been validated with a number of customers. One top 10 pharma company in particular is now looking to include our method in their standard procedures.

Our offering provides the following key benefits:

(i)   Reduce the time taken to do proof of principle studies.
(ii)  Reduce the cost of a xenograft study programme (fewer experiments needed).
(iii) Provide regulatory agencies with a rationale for the design of a clinical study programme
(iv)  Improve the outcome of clinical studies (improving the likelihood of success in clinical studies using
an optimised dosing schedule).

In addition, our techniques can be used to:

(a) Unlock the potential of ´sleeper drugs´ which have failed in clinical trials due to sub-optimal dosing or inappropriate schedules or combinations.
(b) Assess data packages for potential oncology in-licensing candidates.

Piramal Healthcare provides a wide range of API and drug product manufacturing, development and packaging services to meet clinical trial and commercial needs. Working with companies from top 20 pharma to small virtual pharma, Piramal supply product and services to all major pharmaceutical markets. We manufacture and package Phase I - III clinical trials materials through to commercial volumes for API and solid dosage drug product. Approval by the MHRA of our clinical trials packaging and distribution offering means that we can offer clients with products in development, a full service offering from one location. We have built a reputation for offering an excellent manufacturing capability and extremely efficient operating systems that deliver outstanding quality. Combined with our uncompromisingly professional attitude and uniquely flexible approach to meet deadlines, Piramal Healthcare endeavours to provide the solution to your outsourcing requirement.

Plastic Antibodies Ltd is focused on commercialising nanoscale polymer particles that have the same binding characteristics as biological antibodies. Unlike biological antibodies, plastic antibodies can be rapidly generated against a new target in just 1-2 weeks, are stable above 100oC and are resistant to solvents. They have exquisite specificity and high binding affinities and can be chemically anchored to a variety of platforms.

The technology is being applied to diagnostics, separation resins, capture agents and therapeutics

ProImmune is a leading provider of immunology products and services serving a broad range of customers in industry and academia. We are committed to helping our customers take their studies to success through innovation, responsive service and focused application support.

Drawing on over 10 years of expertise in adaptive immunity, our portfolio includes assays for antigen characterization, immunogenicity risk assessment, and immune monitoring.

For antigen characterization and biomarker discovery, our proprietary technologies enable investigators to accelerate the discovery and development of new biopharmaceutical drugs in all areas of major unmet medical need, such as cancer, infectious diseases, and autoimmunity. Used to identify disease state epitopes, ProImmune REVEAL™ assays can save years of validation work for researchers seeking useful biomarkers or immunotherapy targets. For lead optimization of vaccine candidates, ProImmune´s integrated epitope discovery platform and follow-on immune-monitoring assays (all of which can be tailored to customer specifications) are invaluable.

Unwanted immunogenicity to biological components of drugs, consumer products and food ingredients can cause significant complications including reduced efficacy or allergies. In response to this, ProImmune have developed a suite of assays to enable our customers to understand the likely immune effects of an agent at an early stage in its development. We offer ultra-sensitive CFSE T cell proliferation assays, and these can be used in conjunction with our cell-free HLA-peptide binding assays to yield maximum information in a very short time.

We offer unique immune monitoring solutions for clinical trials and immunology research, including tracking antigen-specific immune responses with state of the art ELISpot and flow cytometric analysis techniques. We are part of the UK GLP compliance monitoring program, offering these assays to GLP and GCP conditions.

QCTR is a niche CRO specialising in neurology and psychiatry and orphan diseases. We are recognised internationally as experts in conducting proof of concept, phase II and phase III trials.

We understand that patient recruitment, in this notoriously difficult area, is a critical factor to the overall success and cost of a trial and we utilise our expertise to recruit the right patients in a timely manner and retain them for the duration of the trial.

QCTR are the world's first CRO to deliver 437 patients in less than 12 months for a phase III clinical trial in an orphan indication. This was 37% faster than the average of 4 published studies in this indication and 26% faster than the fastest reported, demonstrating our delivery of study milestones through unsurpassed patient recruitment.

We achieve these results through our:
- specialisation in the field of CNS
- a robust and reliable network of clinicians, some of whom we have been working with for over 15 years
- optimising the clinical trial design to balance the needs of the regulatory bodies, the investigators and the patients.

QCTR also provides its clients with:
- transparent budgeting
- accurate and timely project information
- a practical knowledge of best practice in clinical study design in CNS and orphan disease areas
- knowledge of FDA and EMA regulations relating to CNS indications and orphan diseases
- expertise in attending meetings with FDA and EMA, negotiating Special Protocol Assessment with the FDA and obtaining Scientific Advice with the EMA on specific projects.

SELCIA is a leading worldwide provider of integrated drug discovery, medicinal chemistry and GMP certified 14-C custom radiolabelling services.

Selcia Discovery's capabilities include screening biology, medicinal chemistry with eADME support and in vivo DMPK, ensuring that we are able to deliver drug candidates for our partners. Selcia's CEfrag screen offers an innovative, proprietary methodology to identify mM to pM binding interactions between low molecular weight compounds and a therapeutic target, under physiological conditions. CEfrag is a powerful tool for identifying fragment hits on particularly challenging biological targets. Selcia´s CE technology can be used to study protein-protein interactions.

SELCIA specialise in custom 14C-radiosynthesis for preclinical and clinical ADME studies.

Selcia operate from state-of-the-art laboratories close to London, UK and Boston, USA.

Sera Laboratories International Ltd (Sera Lab) is a leading supplier of control matrices and disease state material from both human and animal models. The company offers the most complete range of human- and animal-based research products in Europe.

Sera Lab supplies serum, plasma, whole blood, tissues, microsomes, S9 fractions and fluids from an extensive range of animal species including African Green Monkey, Baboon, Beagle, Bovine, Cat, Chicken, Chimpanzee, Cynomolgus Monkey, Dog (mongrel), Donkey, Ferret, Gerbil, Goat, Guinea Pig, Hamster, Horse, Marmoset, Mini-Pig, Mouse, Pig, Rabbit, Rat, Rhesus Monkey and Sheep. All animals are drug-naive, fasted prior to collection and are from colonies under veterinary supervision.

Human material includes normal serum, plasma and whole blood; disease state material from donors with a wide range of auto-immune, cancer and other disease states; tissue samples from normal and disease state donors and a cell isolation service for the collection of T cells, B cells, monocytes etc from both normal and disease state donors.

Other products include Cell Culture sera and reagents including FBS, Traditional and Cell Specific media and Recombinant Proteins (cytokines, chemokines, growth factors). A sister production company, APS Ltd, offers Custom Services including Antibody Production, Contract Filtration, Buffer Preparation, Lyophilisation and Kit Manufacture.

Seralab is looking to expand its product portfolio and explore collaborations worldwide - please contact us.

The Smerud Medical Research Group (SMERUD) is a clinical Contract Research Organisation (CRO) operating in the European area with offices in Denmark, Finland, Norway, Sweden, Poland, Russia, United Kingdom. Our activities are primarily focused on general drug development consulting to the biotech industries, and on executing clinical project management, monitoring of phase I-III studies, regulatory affairs, data management and medical writing projects. The company employs about 80 persons, of whom 65 are clinical research, regulatory or biostatistical professionals. We have been operating since 1993 with involvement in more than 600 clinical trials and more than 300 regulatory projects, in addition to approximately 100 projects related to data management, biostatistics and medical writing. Our international management team consists of senior professionals with many years of experience from the international pharmaceutical industry, academia as well as the consultancy business. The local country operational country units, each counting typically 5-18 CRAs, are headed by country managers, all with several years' practical experience in clinical research. International project managers are based in key cities around Europe. Our company also funds internal clinical R&D projects including PhD progammes in collaboration with renowned medical faculties in our region.

Stabilitech is a thermal stabilisation company. Through use of the company's proprietary technology, it has demonstrated thermal stability of live and inactivated viral vaccines and biopharmaceuticals including antibodies and proteins. The company uses excipients which are proprietary in this setting, have been used in clinical settings at least and have relatively low cost of goods. The stabilisation procedures are robust with few additional steps which can readily be integrated into existing cGMP production processes. Stabilitech's technology addresses one of the major issues related to vaccines and other biopharmaceuticals, the need for cold chain, thereby reducing cost and, most importantly, protecting efficacy. Stabilitech's aim is to apply this novel and proprietary technology to the stabilisation of key vaccines and biopharmaceuticals through partnerships.

Sygnature, founded in 2004, is a leading United Kingdom-based provider of integrated drug discovery services to the global pharmaceutical industry. Key areas of expertise include medicinal and synthetic chemistry, computational chemistry and bioscience. Sygnature´s team of more than 50 industry-experienced scientists add considerable value to our clients´ programmes by undertaking key elements of the drug discovery process, such as hit finding, hit-to-lead, lead optimisation and complete integrated drug discovery projects.

Services on offer at Sygnature include:

• Medicinal Chemistry
• Synthetic Chemistry
• Computational Chemistry
• Bioscience (in vitro biology and screening)
• Arrays and Libraries
• Process and Scale-up Chemistry
• ADME/Toxicology (via a strategic alliance with Cyprotex Discovery)